《大行報告》中金降復星醫藥(02196.HK)目標價10%至27.5元 業績遜預期
中金發表報告,指復星醫藥(02196.HK)上半年收入214億元人民幣,按年微升0.2%;純利17.8億元人民幣,按年增15.7%。扣除非經常性項目純利13.7億元人民幣,按年則跌26.3%。
報告稱,受抗疫產品按年下滑、Gland Pharma競爭加劇且部分產線停、美元加息升值導致財務費用和匯兌損失增加等因素影響,復藥上半年和次季扣除非經常性項目純利低於該行預期。
考慮抗疫產品按年下滑、仿制藥競爭加劇等,中金下調對其2023及2024年盈測分別27%及33%,至33億及35億元人民幣,維持「跑贏行業」評級,考慮創新管線順利推進,僅下調H股目標價10%至27.5港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.